---
title: "Iovance Biotherapeutics to Present at Upcoming Conferences"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298037299.md"
description: "On September 4, 2026, in San Carlos, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotech firm specializing in pioneering polyclonal tumor infiltrating lymphocyte (TIL) treatments for cancer patients, revealed that its senior executives will be speaking at several forthcoming conferences."
datetime: "2026-09-04T12:02:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298037299.md)
  - [en](https://longbridge.com/en/news/298037299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298037299.md)
generator: "portal-rs"
---

# Iovance Biotherapeutics to Present at Upcoming Conferences

On September 4, 2026, in San Carlos, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotech firm specializing in pioneering polyclonal tumor infiltrating lymphocyte (TIL) treatments for cancer patients, revealed that its senior executives will be speaking at several forthcoming conferences.

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [IOVA: Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook](https://longbridge.com/en/news/298626037.md)
- [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md)
- [08:00 ETMinistry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio](https://longbridge.com/en/news/298210868.md)
- [Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovation](https://longbridge.com/en/news/298444718.md)
- [ALXO: Biomarker-driven CD47 and novel EGFR ADC programs show promise for hard-to-treat cancers](https://longbridge.com/en/news/298621322.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**